326 related articles for article (PubMed ID: 20199883)
1. Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
Growth Horm IGF Res; 2010 Jun; 20(3):179-84. PubMed ID: 20199883
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone induced lipolysis during short- and long-term administration in adult Prader-Willi patients.
Höybye C; Hilding A; Marcus C; Thorén M
Growth Horm IGF Res; 2005 Dec; 15(6):411-5. PubMed ID: 16230042
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Frystyk J; Christiansen JS; Höybye C
Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
[TBL] [Abstract][Full Text] [Related]
5. Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome.
Höybye C; Thorén M; Böhm B
J Intellect Disabil Res; 2005 Apr; 49(Pt 4):245-52. PubMed ID: 15816811
[TBL] [Abstract][Full Text] [Related]
6. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
Grugni G; Marzullo P; Ragusa L; Sartorio A; Trifirò G; Liuzzi A; Crinò A;
Clin Endocrinol (Oxf); 2006 Oct; 65(4):492-9. PubMed ID: 16984242
[TBL] [Abstract][Full Text] [Related]
7. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome.
Höybye C
Acta Paediatr; 2007 Mar; 96(3):410-3. PubMed ID: 17407467
[TBL] [Abstract][Full Text] [Related]
8. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
Myers SE; Carrel AL; Whitman BY; Allen DB
J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
[TBL] [Abstract][Full Text] [Related]
9. Sleep cycling alternating pattern (CAP) expression is associated with hypersomnia and GH secretory pattern in Prader-Willi syndrome.
Priano L; Grugni G; Miscio G; Guastamacchia G; Toffolet L; Sartorio A; Mauro A
Sleep Med; 2006 Dec; 7(8):627-33. PubMed ID: 17023209
[TBL] [Abstract][Full Text] [Related]
10. Comparison of body composition, basal metabolic rate and metabolic outcomes of adults with Prader Willi syndrome or lesional hypothalamic disease, with primary obesity.
Lloret-Linares C; Faucher P; Coupaye M; Alili R; Green A; Basdevant A; Clément K; Poitou C
Int J Obes (Lond); 2013 Sep; 37(9):1198-203. PubMed ID: 23318724
[TBL] [Abstract][Full Text] [Related]
11. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome.
Lafortuna CL; Minocci A; Capodaglio P; Gondoni LA; Sartorio A; Vismara L; Rizzo G; Grugni G
J Clin Endocrinol Metab; 2014 May; 99(5):1816-24. PubMed ID: 24471571
[TBL] [Abstract][Full Text] [Related]
12. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
Höybye C
Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
[TBL] [Abstract][Full Text] [Related]
13. Body composition in Prader-Willi syndrome compared with nonsyndromal obesity: Relationship to physical activity and growth hormone function.
van Mil EG; Westerterp KR; Gerver WJ; Van Marken Lichtenbelt WD; Kester AD; Saris WH
J Pediatr; 2001 Nov; 139(5):708-14. PubMed ID: 11713451
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
Endocrine; 2012 Apr; 41(2):191-9. PubMed ID: 22081257
[TBL] [Abstract][Full Text] [Related]
15. The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.
Marostica E; Grugni G; De Nicolao G; Marazzi N; Crinò A; Cappa M; Sartorio A
Growth Horm IGF Res; 2013 Dec; 23(6):261-6. PubMed ID: 24090687
[TBL] [Abstract][Full Text] [Related]
16. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity.
Höybye C; Hilding A; Jacobsson H; Thorén M
J Clin Endocrinol Metab; 2002 Aug; 87(8):3590-7. PubMed ID: 12161480
[TBL] [Abstract][Full Text] [Related]
17. Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration.
Rigamonti AE; Grugni G; Marazzi N; Bini S; Bidlingmaier M; Sartorio A
Growth Horm IGF Res; 2015 Aug; 25(4):168-73. PubMed ID: 26059749
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database).
Lindgren AC; Lindberg A
Horm Res; 2008; 70(3):182-7. PubMed ID: 18663319
[TBL] [Abstract][Full Text] [Related]
19. Prader-Willi syndrome: how does growth hormone affect body composition and physical function?
Carrel AL; Allen DB
J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1445-51. PubMed ID: 11837498
[TBL] [Abstract][Full Text] [Related]
20. Body composition during GH treatment in Prader-Labhardt-Willi syndrome.
Bosio L; Beccaria L; Benzi F; Sanzari A; Chiumello G
J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():351-3. PubMed ID: 10698601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
